ProBiora3® Reduces incidence of Dental Decay – Study

Oragenics (NYSE: OGEN) announced the successful completion of an independent study evaluating the effects of a chewable tablet containing ProBiora3, in early childhood development of dental caries in preschool children living in low socioeconomic, multicultural areas.The study was conducted under the guidance of Professor Svante Twetman, . The study employed a randomized double-blind placebo-controlled design consisting of 138 healthy children ranging from two to three years in age. The children were placed into groups that were administered once a day either chewable tablets containing ProBiora3® or a placebo tablet. In conjunction with this study, parents were further instructed to thoroughly brush the children’s teeth in each group twice daily with fluoride toothpaste. Study duration was one year with 66% compliance.Overall, the ProBiora3® administered group observed statistically significant lower dental caries increments than in the placebo group, 0.2 vs. 0.8 (p<0.05).


More on ProBiora3®

468 ad